Literature DB >> 22639409

Trends of stage, grade, histology and tumour necrosis in renal cell carcinoma in a European centre surgical series from 1984 to 2010.

Martin Pichler1, Georg C Hutterer, Thomas F Chromecki, Johanna Jesche, Karin Kampel-Kettner, Katharina Eberhard, Gerald Hoefler, Karl Pummer, Richard Zigeuner.   

Abstract

AIMS: To analyse renal cell carcinoma (RCC) stage, grade, histology and necrosis migration in a large European centre series over the last 27 years.
METHODS: The pathology reports of 2739 consecutive patients with RCC who underwent nephrectomy from 1984 to 2010 at the institution of the authors were systematically re-evaluated. Patients were pooled into five time groups according to the date of surgery: group 1: 1984-1989, group 2: 1990-1994, group 3: 1995-1999, group 4: 2000-2004 and group 5: 2005-2010, respectively. Changes in pT categories according to WHO 2010 classification, tumour grade, histological subtype and presence of tumour necrosis (TN) were evaluated.
RESULTS: Small pT1a tumours were found in 62/485 (12.8%) and 312/639 (48.8%) patients in groups 1 and 5, respectively (p<0.001). Advanced tumour stages (pT3a-4) were found in 306/485 (63.1%) and 171/639 (26.8%) patients in groups 1 and 5, respectively (p<0.001). The number of grade 3/4 tumours increased from 62/485 (12.7%) and 130/639 (20.3%) in groups 1 and 5, respectively, whereas the number of grade 1 tumours decreased over time (p<0.001). There has been a significant histological migration for the chromophobe subtype from 1.1% to 4.3% (p=0.002). The frequency of the presence TN decreased from 41.7% in group 1 to 32.7% in group 5 (p<0.001).
CONCLUSIONS: In contrast to data from Australia but similar to data from US cohorts, a statistically significant stage migration towards small RCCs was observed in this European cohort. Significant changes in tumour grade, histological subtype and TN were also observed.

Entities:  

Mesh:

Year:  2012        PMID: 22639409     DOI: 10.1136/jclinpath-2012-200797

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  10 in total

1.  Expression of IL-4 and IL-13 predicts recurrence and survival in localized clear-cell renal cell carcinoma.

Authors:  Yuan Chang; Le Xu; Huimin An; Qiang Fu; Lian Chen; Zongming Lin; Jiejie Xu
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

2.  Combination of MiR-378 and MiR-210 Serum Levels Enables Sensitive Detection of Renal Cell Carcinoma.

Authors:  Michal Fedorko; Michal Stanik; Robert Iliev; Martina Redova-Lojova; Tana Machackova; Marek Svoboda; Dalibor Pacik; Jan Dolezel; Ondrej Slaby
Journal:  Int J Mol Sci       Date:  2015-09-29       Impact factor: 5.923

Review 3.  Current Insights into Long Non-Coding RNAs in Renal Cell Carcinoma.

Authors:  Maximilian Seles; Georg C Hutterer; Tobias Kiesslich; Karl Pummer; Ioana Berindan-Neagoe; Samantha Perakis; Daniela Schwarzenbacher; Michael Stotz; Armin Gerger; Martin Pichler
Journal:  Int J Mol Sci       Date:  2016-04-15       Impact factor: 5.923

4.  [64Cu]XYIMSR-06: A dual-motif CAIX ligand for PET imaging of clear cell renal cell carcinoma.

Authors:  Il Minn; Soo Min Koo; Hye Soo Lee; Mary Brummet; Steven P Rowe; Michael A Gorin; Polina Sysa-Shah; William D Lewis; Hye-Hyun Ahn; Yuchuan Wang; Sangeeta Ray Banerjee; Ronnie C Mease; Sridhar Nimmagadda; Mohamad E Allaf; Martin G Pomper; Xing Yang
Journal:  Oncotarget       Date:  2016-08-30

5.  Critical evaluation of the potential prognostic value of the pretreatment-derived neutrophil-lymphocyte ratio under consideration of C-reactive protein levels in clear cell renal cell carcinoma.

Authors:  Orietta Dalpiaz; Theresa Luef; Maximilian Seles; Michael Stotz; Tatjana Stojakovic; Karl Pummer; Richard Zigeuner; Georg C Hutterer; Martin Pichler
Journal:  Br J Cancer       Date:  2016-12-01       Impact factor: 7.640

6.  Comparative analysis of histopathological subtypes of renal cell carcinoma in the Middle East compared to other world regions.

Authors:  Mark Khauli; Nassib Abou Heidar; Jad A Degheili; Nizar Hakam; Mouhamad Al-Moussawy; Mohammed Shahait; Jose El-Asmar; Gerges Bustros; Ali Merhe; Rami Nasr; Muhammad Bulbul; Wassim Wazzan; Albert El-Hajj; Ali Shamseddine; Hala Kfoury; Deborah Mukherji; Raja Khauli
Journal:  Urol Ann       Date:  2021-03-04

7.  Imaging of carbonic anhydrase IX with an 111In-labeled dual-motif inhibitor.

Authors:  Xing Yang; Il Minn; Steven P Rowe; Sangeeta Ray Banerjee; Michael A Gorin; Mary Brummet; Hye Soo Lee; Soo Min Koo; Polina Sysa-Shah; Ronnie C Mease; Sridhar Nimmagadda; Mohamad E Allaf; Martin G Pomper
Journal:  Oncotarget       Date:  2015-10-20

8.  Prognostic value of granulocyte colony-stimulating factor in patients with non-metastatic clear cell renal cell carcinoma.

Authors:  Zheng Liu; Yu Zhu; Yiwei Wang; Qiang Fu; Hangcheng Fu; Zewei Wang; Junyu Zhang; Gaoxiang Li; Jiejie Xu; Bo Dai
Journal:  Oncotarget       Date:  2017-07-25

9.  Accurate Risk Assessment of Patients with Pathologic T3aN0M0 Renal Cell Carcinoma.

Authors:  Jong Jin Oh; Jung Keun Lee; Byung Do Song; Hakmin Lee; Sangchul Lee; Seok-Soo Byun; Sang Eun Lee; Sung Kyu Hong
Journal:  Sci Rep       Date:  2018-09-17       Impact factor: 4.379

10.  Long Non-Coding RNA PANTR1 is Associated with Poor Prognosis and Influences Angiogenesis and Apoptosis in Clear-Cell Renal Cell Cancer.

Authors:  Maximilian Seles; Georg C Hutterer; Johannes Foßelteder; Marek Svoboda; Margit Resel; Dominik A Barth; Renate Pichler; Thomas Bauernhofer; Richard E Zigeuner; Karl Pummer; Ondrej Slaby; Christiane Klec; Martin Pichler
Journal:  Cancers (Basel)       Date:  2020-05-10       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.